| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Galapagos NV | GLPG3667 - (GALACELA) | Systemic lupus erythematosus (SLE) | Phase 2 | Ongoing | oral | Immunology |
| Galapagos NV | GLPG3970 - (SEA TURTLE) | Ulcerative Colitis | Phase 2 | Oral | Gastroenterology | |
| Galapagos NV | Filgotinib | Non-infectious uveitis | Phase 2 | Oral | Opthalmic | |
| Galapagos NV | Filgotinib (MANTA) | Inflammatory Bowel Disease | Phase 2 | Oral | Gastroenterology | |
| Galapagos NV | GLPG1972 - (ROCCELLA) | Osteoarthritis | Phase 2b | Trial Completed | Oral | Orthopedic |
| Galapagos NV | GLPG1690 - (NOVESA) | Systemic sclerosis | Phase 2 | oral | Immunology | |
| Galapagos NV | Filgotinib and GS-9876 | Cutaneous lupus erythematosus (CLE) | Phase 2 | Trial Discontinued | Oral | Immunology |
| Galapagos NV | GLPG2737 - (MANGROVE) | Autosomal dominant polycystic kidney disease (ADPKD) | Phase 2 | Trial Completed | Oral | Genetic Disorder |